Gilead Raises Sales Forecast, Cuts Profit Outlook on Deals

Key Financial Updates

Gilead Sciences announced strong first-quarter results that surpassed analyst expectations. However, the company significantly lowered its full-year earnings guidance to a net loss, citing substantial charges related to recent strategic acquisitions.

Quarterly Performance Overview

For the first quarter, the pharmaceutical company reported adjusted earnings of $2.03 per share on revenue of $6.96 billion, exceeding Wall Street forecasts. This performance was driven by demand-driven growth across its business areas, including a 7% rise in sales for its HIV drug Biktarvy.

Impact of Strategic Acquisitions

Gilead now anticipates an adjusted loss for the year between $1.05 and $0.65 per share, a stark contrast to its previous profit estimates. This revision is due to an expected $11.5 billion charge in the second quarter for its acquisitions of Arcellx and other companies. Despite the short-term impact, Gilead raised its overall 2026 sales outlook by $400 million to a range of $30 billion to $30.4 billion.

Summary

Gilead's core business demonstrates robust growth, particularly in its HIV and oncology portfolios. The immediate financial outlook is impacted by the costs of acquisitions intended for long-term expansion, but the company's long-term sales forecast has improved.

FAQ

Q: Why did Gilead cut its full-year profit outlook?
A: The company cut its outlook due to an $11.5 billion charge and financing costs related to its recent acquisitions of Arcellx, Ouro Medicines, and Tubulis.

Q: How did Gilead's revenue perform in the first quarter?
A: First-quarter revenue rose 4% to $6.96 billion, ahead of the $6.91 billion expected by analysts.

Source: Investing.com